Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Fineline Cube May 13, 2026
Company Deals

Mindray Bio-Medical Re-Files for Hong Kong Listing After Initial Application Expiration

Fineline Cube May 12, 2026
Company Deals

Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer

Fineline Cube May 12, 2026
Company Deals

China Medical System Secures Exclusive China Rights to Pharmacosmos’ MonoFer and CosmoFer IV Iron Therapies

Fineline Cube May 12, 2026
Company Deals

Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization

Fineline Cube May 12, 2026
Policy / Regulatory

Hong Kong to Launch FDA-Style Medical Products Regulation Center by Year-End, Creating Gateway for Chinese Innovative Drugs

Fineline Cube May 13, 2026
Company Drug

Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer

Fineline Cube May 13, 2026
Company Drug

Bio-Thera’s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China

Fineline Cube May 13, 2026
Company Medical Device

Acotec Scientific Gains NMPA Approval for AcoArt Verbena Vertebral Balloon

Fineline Cube Jun 6, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has received marketing approval from China’s National Medical...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Study of SHR-A1811, Adebrelimab and Famitinib in Solid Tumors

Fineline Cube Jun 6, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...

Company Deals

Qure Biotechnology Secures RMB 100 Million Series C1 Financing

Fineline Cube Jun 6, 2025

China-based Qure Biotechnology (Shanghai) Co., Ltd. announced the completion of a Series C1 financing round...

Company Drug

Lianhuan Pharma Gains NMPA Approval for No-Spa Generic

Fineline Cube Jun 6, 2025

China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) announced that it has received market clearance...

Company Drug

Roche’s Evrysdi 5mg Tablet Gains EU Commission Approval for Spinal Muscular Atrophy

Fineline Cube Jun 6, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has...

Company Deals

Shanghai OPM Biosciences Plans Acqusition of PharmaLegacy Labs for RMB 1.45 Billion

Fineline Cube Jun 6, 2025

Shanghai OPM Biosciences Co., Ltd (SHA: 688293), a China-based cell culture-focused Contract Development and Manufacturing...

Company Drug

Sunshine Guojian’s SSGJ-613 Meets Phase III Endpoints in Acute Gouty Arthritis

Fineline Cube Jun 6, 2025

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...

Policy / Regulatory

NHSA Strengthens Pharmaceutical Pricing and Procurement Credit Evaluation Mechanism

Fineline Cube Jun 6, 2025

The National Healthcare Security Administration (NHSA) issued a notification this week to refine its credit...

Policy / Regulatory

China Issues Whistleblower Incentives for Drug and Medical Device Safety Violations

Fineline Cube Jun 6, 2025

China’s National Medical Products Administration (NMPA), Ministry of Finance (MoF), and State Administration for Market...

Policy / Regulatory

China’s National Health Commission Mandates Labor Pain Management Services Expansion

Fineline Cube Jun 6, 2025

China’s National Health Commission (NHC) issued a notification mandating the comprehensive promotion of labor pain...

Company Deals

Intragrand Pharma Licenses Lenamilast to Transpire Bio for Global Development

Fineline Cube Jun 6, 2025

China-based Suzhou Intragrand Pharma has entered into a licensing agreement with U.S.-headquartered Transpire Bio Inc....

Company Deals

Consun Pharma Partners with DP Technology to Accelerate AI-Driven Kidney Disease Drug R&D

Fineline Cube Jun 6, 2025

China-based Consun Pharmaceutical Group Ltd (HKG: 1681) announced a strategic partnership with compatriot firm DP...

Company Drug

Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE

Fineline Cube Jun 5, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1/IL-2α-bias bispecific antibody (BsAb) fusion...

Company Drug

BMS Secures NMPA Approval for Reblozyl in Myelodysplastic Syndromes

Fineline Cube Jun 5, 2025

US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) announced that it has received an indication extension...

Company Deals

Shanghai Pharma Partners with Chugai Pharma China to Enhance Bone Health Products

Fineline Cube Jun 5, 2025

China’s Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607; SPH) has established a partnership...

Company Deals

Genrix Bio Partners with Cullinan Therapeutics for GR1803 License

Fineline Cube Jun 5, 2025

China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics,...

Company Drug

AstraZeneca’s Imfinzi Approved for Limited Stage Small Cell Lung Cancer in China

Fineline Cube Jun 5, 2025

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) received approval from China’s National Medical Products Administration...

Company Drug

Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication

Fineline Cube Jun 5, 2025

China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the...

Company Drug

Salubris Pharmaceuticals’ Allisartan-Indapamide Hybrid Wins NMPA Approval

Fineline Cube Jun 5, 2025

Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, announced that it has...

Company Drug

Wantai Biopharm’s Cecolin 9 HPV Vaccine Approved by China’s NMPA

Fineline Cube Jun 5, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its 9-valent human...

Posts pagination

1 … 147 148 149 … 664

Recent updates

  • Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal
  • Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection
  • Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer
  • Bio-Thera’s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China
  • Sichuan Biokin’s Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Company Medical Device

Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection

Company Drug

Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer

Company Drug

Bio-Thera’s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.